Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has disclosed its provisional Q2 2025 consolidated performance, reporting revenue of KRW 1.2899T, operating profit of KRW 475.6B, and net profit of KRW 324.4B. Year-over-year, revenue and operating profit grew by 11.50% and 9.46% respectively, with cumulative Q2 revenue reaching KRW 2.5882T (+23.02% YoY).
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: Provisional Operating Results Based on Consolidated Financial Statements (Fair Disclosure)
- Period Covered: Q2 2025 (Apr 1, 2025 – Jun 30, 2025) and Q2 Cumulative
- Q2 2025 Consolidated Financial Performance (Unit: KRW Million, %):
- Revenue: Current Period 1,289,905 (-0.64% QoQ, +11.50% YoY) / Cumulative 2,588,178 (+23.02% YoY)
- Operating Profit: Current Period 475,600 (-2.28% QoQ, +9.46% YoY) / Cumulative 962,288 (+46.73% YoY)
- Profit Before Income Tax: Current Period 408,905 (-18.12% QoQ, -12.06% YoY) / Cumulative 908,291 (+28.83% YoY)
- Net Profit: Current Period 324,386 (-13.62% QoQ, +2.01% YoY) / Cumulative 699,940 (+40.73% YoY)
- Net Profit Attributable to Owners of Parent: Current Period 324,386 (-13.62% QoQ, +2.01% YoY) / Cumulative 699,940 (+40.73% YoY)
- Information Provision Details:
- Provider: IR Team
- Target Audience: Domestic/International Investors, Press, etc.
- Date & Time: July 23, 2025
- Other Important Details:
- Related materials will be posted on the company website (http://www.samsungbiologics.com).
- Figures are provisional and un-audited, subject to change upon external audit completion.
- Related Disclosure: July 9, 2025: Advance Notice of Financial Results Announcement
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Q2 Provisional Results and Future Finalized Financial Statements
This disclosure provides notice of Samsung Biologics’ Q2 2025 provisional consolidated operating performance.
Reviewing the year-over-year revenue and operating profit growth trend and checking finalized figures in upcoming periodic reports following the external audit is essential.
Relevant developments can be verified in future periodic reports (Half-Year Report) and official IR materials on the company website.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
